AbbVie (ABBV) Total Liabilities (2012 - 2026)

AbbVie (ABBV) has reported Total Liabilities for 15 consecutive years, with $141.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 2.72% year-over-year to $141.0 billion in Q2 2026; TTM through Jun 2026 was $141.0 billion, a 2.72% increase from a year earlier, with the FY2025 full-year figure at $137.2 billion, up 4.12% from the prior year.
• Total Liabilities was $141.0 billion for Q2 2026 at AbbVie, down from $143.1 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $143.1 billion in Q1 2026 and troughed at $121.2 billion in Q1 2023.
• A 5-year average of $131.6 billion and a median of $133.2 billion in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities retreated 7.38% in 2022 and increased 16.15% in 2024, its largest moves.
• Over 5 years, Total Liabilities stood at $121.5 billion in 2022, then gained by 2.3% to $124.3 billion in 2023, then gained by 6.02% to $131.8 billion in 2024, then increased by 4.12% to $137.2 billion in 2025, then increased by 2.78% to $141.0 billion in 2026.
• The last three Total Liabilities figures came in at $141.0 billion (Q2 2026), $143.1 billion (Q1 2026), and $137.2 billion (Q4 2025), per Business Quant data.